Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 2639.

https://doi.org/10.1182/blood-2021-147790

Published: 2021

Journal Articles

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 72.

https://doi.org/10.1182/blood-2021-147729

Published: 2021

Journal Articles

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 71.

https://doi.org/10.1182/blood-2021-146161

Published: 2021

Journal Articles

Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial

Fie Juhl Vojdeman, MD, Lone Bredo Pedersen, Doreen Te Raa, MD PhD, Vesa Juvonen, PhD, Yvette Norden, Geir Erland Tjønnfjord, MD DMsc, Eva Kimby, Maija Itälä-Remes, MD PhD, Anton W Langerak, Ludo M. Evers, Thorsten Zenz, MD, Marinus H.J. Van Oers, MD PhD, Christian H. Geisler, MD PhD, Arnon P. Kater, MD, Carsten Utoft Niemann, MD PhD

Blood (2017) 130 (Supplement 1): 4312.

https://doi.org/10.1182/blood.V130.Suppl_1.4312.4312

Published: 2017

Journal Articles

Alpha1-Antichymotrypsin Present in Therapeutic C1-Inhibitor Products Competes with Selectin - Sialyl Lewis X Interaction

Ruchira Engel, PhD, Laura Delvasto Nunez, Dorina Roem, Gerard van Mierlo, Stephanie Holst, Marinus H.J. Van Oers, MD PhD, Manfred Wuhrer, Prof, Diana Wouters, PhD, Sacha Zeerleder, MD PhD

Blood (2015) 126 (23): 1008.

https://doi.org/10.1182/blood.V126.23.1008.1008

Published: 2015

Journal Articles

Individual Patient Data (IPD) Meta-Analysis of Rituximab Maintenance (MR) for Patients (pts) with Follicular Lymphoma (FL)

Liat Vidal, MDMSc, Anat Gafter-Gvili, MD, Gilles Salles, MDPhD, Sami Bousseta, Bernice Oberman, Carmit Rubin, Marinus H.J. van Oers, MD PhD, Catherine Fortpied, Msc, Ruth Pettengell, MD, Peter Dreger, MD, Mathias Witzens-Harig, MD, Umberto Vitolo, MD, Andrea Evangelista, Maria Gomes da Silva, Hailun Li, Laurence Freedman, PhD, Thomas M Habermann, MD, Ofer Shpilberg, MD

Blood (2014) 124 (21): 4462.

https://doi.org/10.1182/blood.V124.21.4462.4462

Published: 2014

Journal Articles

Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results

Marinus H.J. van Oers, Kazimierz Kuliczkowski, MD PhD Prof., Lukas Smolej, Mario Petrini, Fritz Offner, Sebastian Gorsicki, Mark-David Levin, Ira Gupta, Jennifer Phillips, Vanessa Williams, Steen Lisby, Christian Geisler

Blood (2014) 124 (21): 21.

https://doi.org/10.1182/blood.V124.21.21.21

Published: 2014

Journal Articles

No Increased Risk of Secondary Neoplasms in Patients Treated with Rituximab for Non-Hodgkin’s Lymphoma : A Meta-Analysis of 9 Trials

Isabelle Fleury, MD, Sylvie Chevret, MD PhD, Michael Pfreundschuh, Gilles Salles, MDPhD, Bertrand Coiffier, MD PhD, Marinus H.J. van Oers, Christian Gisselbrecht, MDPhD, Emanuele Zucca, MD, Michael Herold, MDPhD, Michele Ghielmini, MD, Catherine Thieblemont, MDPhD

Blood (2014) 124 (21): 1659.

https://doi.org/10.1182/blood.V124.21.1659.1659

Published: 2014

Journal Articles

No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study

Henk Lokhorst, Bronno van der Holt, PhD, Jan Cornelissen, MD, PhD, Marie José Kersten, MD, PhD, Marinus H.J. Van Oers, MD, PhD, Reinier Raymakers, MD, PhD, Monique C. Minnema, MD PhD, Sonja Zweegman, MD PhD, Jeroen JWM Janssen, MD, Mark Zijlmans, MD, Gerard M.J. Bos, Prof MD PhD, Nicolaas PM Schaap, MD, PhD, Okke de Weerdt, Shulamiet Wittebol, MD, Rianne Ammerlaan, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 2132.

https://doi.org/10.1182/blood.V122.21.2132.2132

Published: 2013

Journal Articles

Possible Mechanisms Of Resistance To The Novel BH3-Mimetic ABT-199 In In Vitro Lymph Node Models Of CLL – The Role Of Abl and Btk

Rachel Thijssen, Christian R Geest, Martin FM de Rooij, Nora Liu, Bogdan I Florea, Katinka Weller, Hermen S Overkleeft, Marinus H.J. Van Oers, MD, PhD, Marcel Spaargaren, PhD, Arnon P. Kater, MD PhD, Eric Eldering, PhD

Blood (2013) 122 (21): 4188.

https://doi.org/10.1182/blood.V122.21.4188.4188

Published: 2013

Journal Articles

R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation

Michel Van Gelder, PhD, MD, Wendim Ghidey, Martine ED Chamuleau, MD, Jan Cornelissen, MD, PhD, Eefke J Petersen, MD PhD, Simon M. G. J. Daenen, Pierre Zachee, MD, PhD, Mels Hoogendoorn, MD, PhD, Aart Beker, MD, Gert Jan Timmers, MD, PhD, Arnon P. Kater, MD PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2013) 122 (21): 2883.

https://doi.org/10.1182/blood.V122.21.2883.2883

Published: 2013

Journal Articles

The Impact Of Subclonal Versus Clonal Novel Recurrent Mutations On Treatment Outcome In Previously Untreated High Risk CLL Patients: Results From The HOVON68 Trial

Doreen te Raa, MD, Arnon P. Kater, MD PhD, Wendim Ghidey Alemayehu, Alexander Jethwa, Jennifer Hullein, Eric Eldering, PhD, Tatjana Stankovic, MD, PhD, Thorsten Zenz, MD, Christian H Geisler, Marinus H.J. Van Oers, MD, PhD

Blood (2013) 122 (21): 2861.

https://doi.org/10.1182/blood.V122.21.2861.2861

Published: 2013

Journal Articles

CMV-Specific CD8 + T-CELL Function Is NOT Impaired In CLL

Doreen te Raa, MD, Fernanda Pascutti, PhD, Juan J Garcia-Vallejo, PhD, Emilie Reinen, Ester B.M. Remmerswaal, René A.W. Van Lier, PhD, Eric Eldering, PhD, Marinus H.J. Van Oers, MD, PhD, Sanne H. Tonino, MD PhD, Arnon P. Kater, MD PhD

Blood (2013) 122 (21): 2862.

https://doi.org/10.1182/blood.V122.21.2862.2862

Published: 2013

Journal Articles

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

Henk Lokhorst, Bronno van der Holt, PhD, Sonja Zweegman, MD PhD, Edo Vellenga, MD, PhD, Sandra Croockewit, MD, Marinus H.J. Van Oers, MD, PhD, Peter von dem Borne, MD, PhD, Pierre W. Wijermans, MD, PhD, M. R Schaafsma, MD, PhD, Okke de Weerdt, Shulamiet Wittebol, MD, Michel Delforge, MD, PhD, Gerard M.J. Bos, Prof MD PhD, Harm Sinnige, Marinus MarwijkKooy, Peter Joosten, MD, Monique C. Minnema, MD PhD, Rianne Ammerlaan, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 3332.

https://doi.org/10.1182/blood.V122.21.3332.3332

Published: 2013

Journal Articles

The Broad Kinase Inhibitor Dasatinib in Combination with Fludarabine in Patients with Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase 2 Study

Arnon P. Kater, MD PhD, Marjolijn Spiering, Rob D Liu, Marielle M Beckers, Sanne H. Tonino, Simon M. G. J. Daenen, Jeanette K Doorduijn, Nienke A Lankheet, Dieuwertje M Luijks, Doreen te Raa, MD, Eric Eldering, PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2012) 120 (21): 1798.

https://doi.org/10.1182/blood.V120.21.1798.1798

Published: 2012

Journal Articles

SF3B1 Mutations in CLL Are Equivalent to p53/ATM Dysfunction and Cause Defective Puma Upregulation in Response to Chemotherapy

Doreen te Raa, MD, Ingrid AM Derks, Dieuwertje M Luijks, Jacoline van Laar, Hanneke Monsuur, Ceri Oldreive, Alexander Jethwa, Jennifer Hüllein, Tatjana Stankovic, MD PhD, Thorsten Zenz, MD, Marinus H.J. Van Oers, MD, PhD, Arnon P. Kater, MD PhD, Eric Eldering, PhD

Blood (2012) 120 (21): 711.

https://doi.org/10.1182/blood.V120.21.711.711

Published: 2012

Journal Articles

Mapping the Targets of Dasatinib in Chronic Lymphocytic Leukemia Reveals Distinct Roles for Abl and Btk in Drug Resistance and Adhesion, and Explains Clinical Effects On Lymph Node Reduction

Eric Eldering, PhD, Christian R Geest, Martin FM de Rooij, Nora Liu, Bogdan I Florea, Marinus H.J. Van Oers, MD, PhD, Hermen S Overkleeft, Marcel Spaargaren, PhD, Arnon P. Kater, MD PhD

Blood (2012) 120 (21): 3900.

https://doi.org/10.1182/blood.V120.21.3900.3900

Published: 2012

Journal Articles

Role of T Cell-Derived IL-21 in the Proliferation of Chronic Lymphocytic Leukemia Cells,

Maria F. Pascutti, PhD, Jacqueline M. Tromp, MD, Margot Jak, MD, Ingrid A.M. Derks, Rene A.W. van Lier, PhD, Steven T. Pals, MD, PhD, Marinus H.J. Van Oers, MD, PhD, Arnon P Kater, MD, PhD, Eric Eldering, PhD

Blood (2011) 118 (21): 3871.

https://doi.org/10.1182/blood.V118.21.3871.3871

Published: 2011

Journal Articles

C1-Inhibitor Rescues Red Blood Cells From Complement Mediated Destruction in Autoimmune Hemolytic Anemia

Diana Wouters, PhD, Stephan Femke, Masja de Haas, MD, PhD, Conny Brouwer, Paul Strengers, MD PhD, Anton Hagenbeek, MD, PhD, Marinus H.J. Van Oers, MD, PhD, Sacha Zeerleder, MD PhD

Blood (2011) 118 (21): 716.

https://doi.org/10.1182/blood.V118.21.716.716

Published: 2011

Journal Articles

Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial

Christian H Geisler, MD, PhD, Mars MB van 't Veer, MD, PhD, Wim van Putten, MSc, Jesper Jurlander, MD.PHD, Jan Walewski, MD, PhD, Geir Tjonnfjord, MD, PHD, Maija Itälä-Remes, MD, PHD, Eva Kimby, M.D., Ph.D., Tomas Kozak, MD, PhD, Aaron Polliack, MD, Shulamiet Wittebol, MD, Fokje Spoelstra, PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2011) 118 (21): 290.

https://doi.org/10.1182/blood.V118.21.290.290

Published: 2011

NARROW

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial

Alpha1-Antichymotrypsin Present in Therapeutic C1-Inhibitor Products Competes with Selectin - Sialyl Lewis X Interaction

Individual Patient Data (IPD) Meta-Analysis of Rituximab Maintenance (MR) for Patients (pts) with Follicular Lymphoma (FL)

Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results

No Increased Risk of Secondary Neoplasms in Patients Treated with Rituximab for Non-Hodgkin’s Lymphoma : A Meta-Analysis of 9 Trials

No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study

Possible Mechanisms Of Resistance To The Novel BH3-Mimetic ABT-199 In In Vitro Lymph Node Models Of CLL – The Role Of Abl and Btk

R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation

The Impact Of Subclonal Versus Clonal Novel Recurrent Mutations On Treatment Outcome In Previously Untreated High Risk CLL Patients: Results From The HOVON68 Trial

CMV-Specific CD8 + T-CELL Function Is NOT Impaired In CLL

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

The Broad Kinase Inhibitor Dasatinib in Combination with Fludarabine in Patients with Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase 2 Study

SF3B1 Mutations in CLL Are Equivalent to p53/ATM Dysfunction and Cause Defective Puma Upregulation in Response to Chemotherapy

Mapping the Targets of Dasatinib in Chronic Lymphocytic Leukemia Reveals Distinct Roles for Abl and Btk in Drug Resistance and Adhesion, and Explains Clinical Effects On Lymph Node Reduction

Role of T Cell-Derived IL-21 in the Proliferation of Chronic Lymphocytic Leukemia Cells,

C1-Inhibitor Rescues Red Blood Cells From Complement Mediated Destruction in Autoimmune Hemolytic Anemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only